Source-grounded facts extracted from Advanced Biomed Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Advanced Biomed Inc. issued 270,000 shares of common stock to Mr. Xiaomin Chen for $1,080,000.
“n aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026. Item 3.02 Unregistered Sales”
Advanced Biomed Inc. completed an acquisition involving Acellent Technologies (Hong Kong) Co. Limited for $1,080,000 (closed 2026-04-30).
“Pursuant to the Share Purchase Agreement, the Company agreed to acquire 100% of the equity interest in the Target in exchange for the issuance of 270,000 shares of the Company’s common stock, par value $0.001 per share, valued at $4.00 per share, for an aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026.”
Xiaomin Chen was appointed as Chief Executive Officer, director and Chairman of the Board at Advanced Biomed Inc..
“the Board of Directors appointed Mr. Xiaomin Chen as Chief Executive Officer, director and Chairman of the Board of the Company, effective as of April 28, 2026.”
Yi Lu departed as Chief Executive Officer, director and Chairman of the Board at Advanced Biomed Inc..
“The Company and Mr. Yi Lu, the Company’s Chief Executive Officer, director and Chairman of the Board, have mutually agreed that a leadership transition is necessary and in the best interests of the Company.”
Advanced Biomed Inc. entered into Loan Agreement with Jie Wang valued at US$600,000 (effective 2026-04-13).
“On April 13, 2026, Advanced Biomed Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Jie Wang”
Advanced Biomed Inc. entered into Share Purchase Agreement with Acellent Technologies (Hong Kong) Co. Limited and the sole shareholder of the Target valued at 270,000 shares of the Company’s common stock, par value $0.001 per share, with an estimated value of (effective 2026-04-02).
“On April 2, 2026, Advanced Biomed Inc. (the “Company”) entered into a Share Purchase Agreement (the “Agreement”) with Acellent Technologies (Hong Kong) Co. Limited (the “Target”) and the sole shareholder of the Target (the “Seller”), pursuant to which the Company agreed to purchase from Seller 100% of the equity interest in the Target (the “Acquisition”).”
Advanced Biomed Inc.: Amended certificate of incorporation to effect a 1-for-20 reverse stock split, effective February 20, 2026, with no change to authorized shares or par value (effective 2026-02-20).
“On February 3, 2026, Advanced Biomed Inc. (the “Company”) filed with the Secretary of State of the State of Nevada an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-20 (the “Reverse Stock Split”).”
Advanced Biomed Inc. issued 1,650,710 shares of common stock to the Investor for $500,000.
“the Company issued 1,650,710 shares of Common Stock to the Investor as the consideration for its commitment under the Agreement, with an aggregate value of $500,000 at the time of issuance”
Advanced Biomed Inc. issued 4,000,000 shares of common stock to certain investors for $0.062 per share for a total purchase price of $248,000.
“On January 28, 2026, Advanced Biomed Inc., a Nevada Corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”) relating to the issuance and sale of 4,000,000 shares of common stock (the “Purchased Shares”), par value $0.001 per share, of the Company (the “Common Stock”), at $0.062 per share for a total purchase price of $248,000”
Advanced Biomed Inc. entered into Securities Purchase Agreement with certain investors valued at $248,000 (effective 2026-01-28).
“On January 28, 2026, Advanced Biomed Inc., a Nevada Corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”) relating to the issuance and sale of 4,000,000 shares of common stock (the “Purchased Shares”), par value $0.001 per share, of the Company (the “Common Stock”), at $0.062 per share for a total purchase price of $248,000 (the “Purchase Price”).”
Advanced Biomed Inc. amended Supplemental Agreement with Wei Ha Hui (the Buyer) (effective 2026-01-26).
“On January 26, 2026, the Company entered into a Supplemental Agreement (the "Supplemental Agreement") with Advanced Biomed (HK) Limited and the Buyer in connection with the Spin-Off Agreement.”
Advanced Biomed Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 16, 2026, the Staff notified the Company that its securities would be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 27, 2026, unless the Company requested an appeal of this determination by January 23, 2026 before a Hearings Panel (the “Panel”). On January 21, 2026, the Company appealed the Staff’s delisting determination by submitting a hearing request to the Panel, which stayed the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. The Company expects to present to the Pan”
Advanced Biomed Inc. entered into Share Purchase Agreement with Wei Ha Hui valued at Purchase price of US$23,000 for 100% of Advanced Biomed (HK) Limited (effective 2025-12-23).
“On December 23, 2025, Advanced Biomed Inc. (the “ Company ”) entered into an agreement (the “ Agreement ”) with an unrelated third party, Wei Ha Hui (the “ Buyer ”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “ Hong Kong Subsidiary ”), for an aggregate purchase price of US$23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement.”
Advanced Biomed Inc. completed a disposition involving Wei Ha Hui for US$23,000 (closed 2025-12-23).
“ntered into an agreement (the “ Agreement ”) with an unrelated third party, Wei Ha Hui (the “ Buyer ”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company”
Advanced Biomed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“July 18, 2025, Advanced Biomed Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 32 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade o”
Steven I-Fang Cheng was appointed as Member of the Board of Directors at Advanced Biomed Inc..
“On May 23, 2025, the Board of Directors of the Company appointed Mr. Steven I-Fang Cheng as a member of the Board of Director, effective May 23, 2025.”
Dr. Hung To Pau resigned as Director at Advanced Biomed Inc..
“On May 23, 2025, the Board of Directors of Advanced Biomed Inc. (the “Company”) accepted the resignation of Dr. Hung To Pau from the Board of Directors for personal reasons.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.